Most importantly, the authors revealed that the combined use of a miR-1246 inhibitor and Paclitaxel in an intraperitoneal orthotopic ovarian cancer model led to reduced tumor burden in vivo, despite the fact that Kanlikilicer and colleagues did not isolate exosomes from patient samples but only evaluated the presence of miR-1246 and exosome markers such as CD63 in ovarian tumor samples (n = 15), as well as in normal ovarian surface epithelium samples (n = 7). The gene discussed is CD63; the disease is ovarian carcinoma.